Marie Paraiso, MD
Urogynecology and Reconstructive Pelvic Surgery · Cleveland, OHNPI 1669417770
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Boston Scientific at 45.0% of the total. Reporting peaked in 2024 at $8,059 and has fallen 76.5% since, to $1,891 in 2025.
Across 111 payments — averaging $178.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$9K
- Asensus Surgical, Inc.$7K
- Caldera Medical, Inc$809
- Axonics, Inc.$743
- Coloplast$619
- Medtronic$571
- plus $804 from 11 others
Across 10 payments — averaging $2878.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$27K
- Integra Lifesciences Corporation$1K
What the payments were for
- Consulting fees$10,35552%
- Travel & lodging$3,13816%
- Food & beverage$6,22831%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 40 | $8,894 |
| Asensus Surgical, Inc. | 17 | $7,339 |
| Caldera Medical, Inc | 11 | $809 |
| Axonics, Inc. | 12 | $743 |
| Coloplast | 7 | $619 |
| Medtronic(2 entities) | 9 | $571 |
| Intuitive Surgical | 2 | $247 |
| BD | 1 | $143 |
| Hologic Inc | 1 | $109 |
| Johnson & Johnson(2 entities) | 2 | $69 |
| Astellas Pharma US Inc | 2 | $56 |
| Conmed Corporation | 2 | $43 |
| Baxter Healthcare | 1 | $37 |
| Applied Medical Resources Corporation | 1 | $37 |
| Femselect Inc. | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Cook Medical LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senhance$2,310
- Advantage System$633
- Axonics$421
- ALTIS$401
- INTERSTIM$379
- Solyx SIS System$285
- UPSYLON$264
- Da Vinci Surgical System$247
- Desara$215
- Bulkamid$149
- PROGEL$143
- ACESSA PROVU SYSTEM$109
- GENERAL PELVIC ORGAN PROLAPSE$100
How this compares
$19,779 in reported general payments places this provider in the 85th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
See all urogynecology and reconstructive pelvic surgery providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 13 | $18,142 |
| MyrbetriqMirabegron | 11 | $12,860 |
| Estradiol | 90 | $7,528 |
| Trospium Chloride ErTrospium Chloride | 11 | $3,986 |
| Trospium Chloride | 31 | $2,417 |
| Estradiol (Once Weekly)Estradiol | 13 | $1,705 |
| YuvafemEstradiol | 12 | $1,687 |
| Solifenacin Succinate | 13 | $670 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $657 |
| Cephalexin | 12 | $52 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $22 | $18,14213 claims |
| Astellas Pharma US IncMyrbetriq | $56 | $12,86011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
Other urogynecology and reconstructive pelvic surgery in Cleveland
- Emily SlopnickCleveland$37K
- Ly Hoang RobertsCleveland$23K
- Omer AnisCleveland$17K
- Chen ShenharCleveland$13K
- Amy ParkCleveland$11K
- Katie PropstCleveland$6K
- Anne SammarcoCleveland$5K
- Amy GeeCleveland$5K
- Shannon WallaceCleveland$5K
- Graham ChapmanCleveland$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.